Several molecular biomarkers associated with the occurrence and progression of neuroblastoma have been reported, including MYCN, a clinically recognized oncogenic transcription factor-related biomarker, anaplastic lymphoma kinase (ALK) (20), and PHOX2B (21, 22). This evidence concerns the gene MYCN and neuroblastoma.